This was evident also for blasts carrying poor-prognosis mutations such as FLT3-ITD.47 More extensive studies are needed to elucidate resistant and susceptible AML subtypes, also considering the genetic makeup of the AML clone(s), to enable patient stratification in a precision immunotherapy pipeline. This evidence concerns the gene FLT3 and acute myeloid leukemia.